RSLS OBALON THERAPEUTICS INC

ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference

ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference

SAN CLEMENTE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- ™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer and Tom Stankovich, Chief Financial Officer, will be participating in one-on-one meetings with institutional investors during the A.G.P. Virtual MedTech Conference, taking place Thursday, September 21, 2022.

Investors participating in the virtual conference who are interested in meeting with ReShape’s management team should contact their A.G.P. representative.

About ReShape Lifesciences™

ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. Reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. For more information, please visit ,

CONTACTS

ReShape Lifesciences Investor Contact:

Thomas Stankovich

Chief Financial Officer

949-276-6042

Investor Relations Contact:

Rx Communications Group

Michael Miller

(917)-633-6086



EN
14/09/2022

Underlying

RSLSOBALON THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on OBALON THERAPEUTICS INC

 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting...

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders Partial Adjournment for Proposal 2, Asset Sale Proposal, and Proposal 3, Charter Amendment Proposal; All Other Proposals Required for Merger Were Approved Stockholders are encouraged to vote FOR Proposals 2 and 3 by Calling 1-877-750-8310 (from the U.S. and Canada) or (from other countries) IRVINE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it conducted a Special Meeting of Sto...

July 24, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit Company to Host Pre-Eminent Lap-Band® Surgeon Advocates For a Three-Day Seminar, August 1-3, 2025 IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host its inaugural Lap-Band® Surgeon Summit, taking place August 1-3, 2025 in Nashville, Tennessee. Dr. Christine Ren-Fielding, M.D., Professor of Surgery at NYU Grossman School of Medicine, Director of the NYU Langone Weight Management Program, and Chief of t...

July 22, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® to Host Special Meeting of Stockholders on July ...

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025 Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET on July 24, 2025. A...

July 21, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric B...

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System Patent Enhances and Broadens the Company’s Intellectual Property Portfolio Around a Swallowable and Degradable Intragastric Device IRVINE, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on July 8, 2025 the U.S. Patent and Trademark Office (USPTO) will issue U.S. Patent 12,350,179, entitled, “Intragastric Device.” The patent, related to the Company’s application 18/241,151 an...

July 1, 2025 1 EN
 PRESS RELEASE
Free
RSLS OBALON THERAPEU...

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockhold...

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement IRVINE, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that on June 23, 2025, it received formal notice from The Nasdaq Stock Market, LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq's stockholders equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market....

June 27, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch